Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta-analysis.
Ravina BarrettBrian R BirchPublished in: BJUI compass (2023)
Triptorelin therapy may offer an effective treatment option for men with PCa experiencing moderate to severe LUTS. Its positive impact on QoL can lead to improved patient well-being and treatment adherence. Clinicians should consider triptorelin as a potential treatment choice, especially in patients who may be reluctant to undergo surgical interventions for their LUTS. However, careful patient selection and close monitoring are essential due to the observed study heterogeneity and risk of bias. Future research should focus on evaluating triptorelin's cost-effectiveness and comparing its efficacy with other LH-RH agonists in managing LUTS in PCa patients.Video Abstract: URL (Reviewers/Editors to select from) Link 1: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=071419c8-1ad5-4502-a222-b04300c2ca5e Link 2: https://brighton.cloud.panopto.eu/Panopto/Pages/Viewer.aspx?id=b6305a8a-b977-4fcd-a69e-b04300bed728.
Keyphrases
- lower urinary tract symptoms
- benign prostatic hyperplasia
- systematic review
- prostate cancer
- case report
- end stage renal disease
- physical activity
- stem cells
- palliative care
- bone marrow
- risk assessment
- adipose tissue
- combination therapy
- mesenchymal stem cells
- high intensity
- replacement therapy
- weight loss
- decision making
- insulin resistance
- drug induced
- human health